Effects of indomethacin and celecoxib on renal function in athletes

Medicine and Science in Sports and Exercise

Volumn 37, Issue 5, 2005, Pages 712-717

  Baker, Jordan ^a   Cotter, James D ^b   Gerrard, David F ^a   Bell, Melanie L ^a   Walker, Robert J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

COX 2 inhibitors; Exercise; Kidney; Nonsteroidal antiinflammatory drugs; Randomized placebo controlled trial

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; PLACEBO;

ADULT; AEROBIC CAPACITY; ARTICLE; ATHLETE; BRAIN EDEMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDURANCE; ENZYME INHIBITION; EXERCISE; FREE WATER CLEARANCE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; HYDRATION; HYPONATREMIA; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PERFUSION; MALE; NORMAL HUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; BODY WATER; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; EXERCISE TEST; GLOMERULAR FILTRATION RATE; HUMANS; INDOMETHACIN; KIDNEY; MALE; MIDDLE AGED; PYRAZOLES; SPORTS; SULFONAMIDES;

EID: 18244365601     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1249/01.MSS.0000162700.66214.CE     Document Type: Article

References (25)

1. AYUS, J. C., J. VARON, and A. I. ARIEFF. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann. Intern. Med. 132:711-714, 2000.
2. BOMBARDIER, C., L. LAINE, A. REICIN, et al. VIGOR study group: comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343:1520-1528, 2000.
3. CASTROP, H., F. SCHWEDA, K. SCHUMACHER, K. WOLF, and A. KURTZ. Role of renocortical cyclooxygenase 2 for renal vascular resistance and macula densa control of renin secretion. J. Am. Soc. Nephrol. 12:867-874, 2001.
4. DAVIS, D. P., J. S. VIDEEN, A. MARINO, et al. Exercise-associated hyponatremia in marathon runners: a two-year experience. J. Emerg. Med. 21:47-57, 2001.
5. DAVIES, N. M., A. J. MCLACHLAN, R. O. DAY, and K. M. WILLIAMS. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 38: 225-242, 2000.
6. FARQUHAR, W. B., A. L. MORGAN, E. J. ZAMBRASKI, and W. L. KENNEY. Effects of acetaminophen and ibuprofen on renal function in the stressed kidney. J. Appl. Physiol. 86:598-604, 1999.
7. FRITZSCHE, R. G., and E. F. COYLE. Cutaneous blood flow during exercise is higher in endurance-trained humans. J. Appl. Physiol. 88:734-744, 2000.
8. HARRIS, R. C. Cyclooxygenase-2 in the kidney. J. Am. Soc. Nephrol. 11:2387-2394, 2000.
9. HEW, T. D., J. N. CHORLEY, J. C. CIANCA, and J. G. DIVINE. The incidence, risk factors, and clinical manifestations of hyponatremia in marathon runners. Clin. J. Sport Med. 13:41-47, 2003.
10. HSIEH, M., R. ROTH, D. L. DAVIS, H. LARRABEE, and C. W. CALLAWAY. Hyponatremia in runners requiring on-site medical treatment at a single marathon. Med. Sci. Sports Exerc. 34:185-189, 2002.
11. KAMMERL, M. C., R. M. NUSING, H. W. SEYBERTH, G. A. RIEGGER, A. KURTZ, and B. K. KRAMER. Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. Pflugers Arch. 442:842-847, 2001.
12. KHAN, K. N., S. K. PAULSON, K. M. VERBURG, J. B. LEFKOWITH, and T. J. MAZIASZ. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. 61:1210-1219, 2002.
13. NOAKES, T. Hyponatremia in distance runners: fluid and sodium balance during exercise. Curr. Sports Med. Rep. 1:197-207, 2002.
14. POORTMANS, J. R. Exercise and renal function. Sports Med. 1:125-157, 1984.
15. ROSSAT, J., M. MAILLARD, J. NUSSBERGER, H. R. BRUNNER, and M. BURNIER. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. 66: 76-84, 1999.
16. SAKURADA, S., and J. R. HALES. A role for gastrointestinal endotoxins in enhancement of heat tolerance by physical fitness. J. Appl. Physiol. 84:207-214, 1998.
17. SANCHEZ, P. L., L. M. SALGADO, N. R. FERRERI, and B. ESCALANTE. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34:848-853, 1999.
18. SCHWARTZ, J. L, K. VANDORMAEL, M. P. MALICE, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin. Pharmacol. Ther. 72:50-61, 2002.
19. SPEEDY, D. B., I. R. ROGERS, T. D. NOAKES, et al. Exercise-induced hyponatremia in ultradistance triathletes is caused by inappropriate fluid retention. Clin. J. Sport Med. 10:272-278, 2000.
20. SWAN, S. K., D. W. RUDY, K. C. LASSETER, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann. Intern. Med. 133:1-7, 2000.
21. THERLAND, K. L., J. STUBBE, H. C. THIESSON, et al. Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is co-localised with vascular prostaglandin E2 EP4 receptors. J. Am. Soc. Nephrol. 15:1189-1198, 2004.
22. VRIJENS, D. M., and N. J. REHRER. Sodium-free fluid ingestion decreases plasma sodium during exercise in the heat. J. Appl. Physiol. 86:1847-1851, 1999.
23. WALKER, R., P. FAWCETT, E. FLANNERY, and D. GERRARD. Indomethacin potentiates exercise-induced reduction in renal hemodynamics in athletes. Med. Sci. Sports Exerc. 26:1302-1306, 1994.
24. WHELTON, A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 34:13S-24S, 1999.
25. WHELTON, A., W. B. WHITE, A. E. BELLO, J. A. PUMA, and J. G. FORT. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > 65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 90:959-963, 2002.